Surabhi Dangi-Garimella, PhD

Articles

Study Finds HCV Infection Increases 10-Year Risk of Cardiovascular Disease

December 14, 2018

A combined analysis of data gathered from the Canadian Health Measures Survey and the US–National Health and Nutrition Examination Survey found a 2.5% to 3.5% increase in the 10-year risk of cardiovascular disease in patients with a hepatitis C virus (HCV) infection.

Longer-Term JULIET Results Confirm Sustained Response With Tisagenlecleucel in Relapsed/Refractory DLBCL

December 06, 2018

A median 19-month follow-up of the JULIET trial—a single-arm, open-label, multicenter, global, pivotal phase 2 trial of the chimeric antigen receptor-T cell therapy tisagenlecleucel directed against CD19-expressing B cells—has found a 40% complete response and a manageable safety profile in adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

HBV Reactivation a Serious Adverse Effect of DAAs in the Treatment of HCV

December 06, 2018

A kidney transplant patient treated with direct-acting antivirals (DAAs) for a chronic hepatitis C virus (HCV) infection showed reactivation of the hepatitis B virus (HBV), which proved fatal. The authors of the report recommend a call to action for including HBV testing as part of the patient’s work-up in transplant recipients who are on immunosuppressants, especially in the context of abnormal liver tests.

iLLUMINATE: Superior PFS With Ibrutinib–Obinutuzumab Even in High-Risk, Untreated CLL/SLL

December 03, 2018

Ibrutinib combined with obinutuzumab had better progression-free survival (PFS) at 30 months than the standard chemoimmunotherapy regimen, chlorambucil plus obinutuzumab, regardless of high-risk genomic features in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic leukemia (SLL) who had never been treated.

ASH-EHA Joint Symposium Dives Deep Into the Leukemia–Down Syndrome Connection

December 03, 2018

While several associations between constitutional syndromes, such as Down syndrome, and predisposition to cancers have been recognized, recommendations for surveillance or clear association between the 2 are lacking.

Ibrutinib Alone Better Than Chemoimmunotherapy as Frontline in Older Patients With CLL

December 03, 2018

According to the results of Alliance A041202, an international multicenter phase 3 trial, ibrutinib produces superior progression-free survival (PFS) compared with standard chemoimmunotherapy in older patients with chronic lymphocytic leukemia (CLL) and adding rituximab does not improve the ibrutinib response.

Length of Hospital Stay Key Driver of Costs Associated With CRS Following CAR T Treatment

December 02, 2018

Health resource utilization data gathered from the TRANSCEND-NHL trial have found that longer stays in the intensive care unit have a significant impact on the cost of care due to cytokine release syndrome (CRS) following treatment with chimeric antigen receptor (CAR) T cells.

Studies at ASH Evaluate Episodic ED Utilization, Adherence, QOL in Sickle Cell Disease

December 02, 2018

Patients with sickle cell disease (SCD) typically face episodic emergency department (ED) and inpatient encounters, and innovative interventions are necessary to improve adherence to hydroxyurea treatment among youth suffering from SCD. These were the findings of 2 studies presented during an outcomes research session at the 60th American Society of Hematology Annual Meeting & Exposition.

Real-World Evidence With Axicabtagene Ciloleucel CAR T Treatment Similar to ZUMA-1 Trial Findings

December 02, 2018

A multicenter retrospective study that evaluated the efficacy and safety of chimeric antigen receptor (CAR) T-cell treatment, axicabtagene ciloleucel (axi-cel; Yescarta), in a real-world setting found a similar response as well as toxicity compared with the ZUMA-1 clinical trial.

Canadian Health Agencies Release Physical Activity Guidance During Pregnancy

December 01, 2018

The Society of Obstetricians and Gynaecologists of Canada and the Canadian Society for Exercise Physiology have released consensus guidelines that will provide guidance for pregnant women as well as their clinical care providers on prenatal physical activity.